98-31854. Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-The-Counter Human Use; Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination With Antacid Drug Products; Correction  

  • [Federal Register Volume 63, Number 230 (Tuesday, December 1, 1998)]
    [Rules and Regulations]
    [Pages 66015-66017]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-31854]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 343
    
    [Docket No. 77N-094A]
    
    
    Internal Analgesic, Antipyretic, and Antirheumatic Drug Products 
    for Over-The-Counter Human Use; Final Rule for Professional Labeling of 
    Aspirin, Buffered Aspirin, and Aspirin in Combination With Antacid Drug 
    Products; Correction
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule; correction.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is correcting a final 
    rule that appeared in the Federal Register of October 23, 1998 (63 FR 
    56802). The document provided for professional labeling for over-the-
    counter (OTC) internal analgesic, antipyretic, and antirheumatic drug 
    products containing aspirin, buffered aspirin, and aspirin in 
    combination with an antacid. The document published with some 
    inadvertent editorial errors. This document corrects those errors.
    
    EFFECTIVE DATE: The regulation is effective October 25, 1999.
    
    FOR FURTHER INFORMATION CONTACT: Ida I. Yoder, Center for Drug 
    Evaluation and Research (HFD-560), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-827-2222.
    
    SUPPLEMENTARY INFORMATION: In FR Doc. 98-28519, appearing on page 
    56802, in the Federal Register of October 23, 1998, the following 
    corrections are made:
         1. On page 56809, in Table 5, in the second entry in the fourth 
    column, ``-3.9'' is corrected to read ``-39''.
         2. On page 56810, in the third column, in the eighteenth line, 
    ``preoperative'' is corrected to read ``perioperative''.
         3. On page 56812, in the first column, in the third paragraph, in 
    the eighteenth line, ``were'' is corrected to read ``was''.
    
    
     Sec. 343.80   [Corrected]
    
         4. On page 56817, in Sec. 343.80(a)(1), the last paragraph is 
    corrected to read ``REV: October 23, 1998''.
    
    [[Page 66016]]
    
        5. On page 56818, in Sec. 343.80(a)(2), the entire page 
    ``HIGHLIGHTS OF PRESCRIBING INFORMATION'' is corrected to read as 
    follows:
    
        Dated: November 20, 1998.
     William K. Hubbard,
     Associate Commissioner for Policy Coordination.
    [FR Doc 98-31854 Filed 11-30-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    [[Page 66017]]
    
    [GRAPHIC] [TIFF OMITTED] TR01DE98.008
    
    
    
    [FR Doc. 98-31854 Filed 11-30-98; 8:45 am]
    BILLING CODE 4160-01-C
    
    
    

Document Information

Effective Date:
10/25/1999
Published:
12/01/1998
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule; correction.
Document Number:
98-31854
Dates:
The regulation is effective October 25, 1999.
Pages:
66015-66017 (3 pages)
Docket Numbers:
Docket No. 77N-094A
PDF File:
98-31854.pdf
CFR: (1)
21 CFR 343.80